United Therapeutics Corporation (UTHR)

United Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, United Therapeutics stock has a consensus rating of "Buy" and an average price target of $665.23. The average 1-year stock price forecast is 17.03% higher than the current stock price, while the lowest is $516 (-9.22%) and the highest is $750 (+31.94%).

Price Target: $665.23 (+17.03%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$516	$665.23	$685	$750
Change	-9.22%	+17.03%	+20.51%	+31.94%

Analyst Ratings

The average analyst rating for United Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	4	4	5	5	5	5
Buy	4	4	4	5	5	6
Hold	4	4	4	4	4	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	13	14	14	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Lisa Walter RBC Capital	RBC Capital	Buy Maintains $707 → $701	Buy	Maintains	$707 → $701	+23.32%	May 7, 2026
Benjamin Burnett Wells Fargo	Wells Fargo	Hold → Buy Upgrades $575 → $738	Hold → Buy	Upgrades	$575 → $738	+29.83%	May 7, 2026
Terence Flynn Morgan Stanley	Morgan Stanley	Hold Maintains $471 → $519	Hold	Maintains	$471 → $519	-8.70%	Apr 10, 2026
Andrew S. Fein HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $600 → $660	Strong Buy	Maintains	$600 → $660	+16.11%	Mar 31, 2026
Benjamin Burnett Wells Fargo	Wells Fargo	Hold Maintains $486 → $575	Hold	Maintains	$486 → $575	+1.16%	Mar 31, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.32B

Increased by 4.35%

from 3.18B

Revenue Next Year

3.80B

Increased by 14.42%

from 3.32B

EPS This Year

29.07

Increased by 4.33%

from 27.86

EPS Next Year

33.25

Increased by 14.39%

from 29.07

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.69B	1.94B	2.33B	2.88B	3.18B	3.32B	3.80B
Revenue Growth	13.63%	14.88%	20.20%	23.63%	10.61%	4.35%	14.42%
EPS	10.06	15.00	19.81	24.64	27.86	29.07	33.25
EPS Growth	-12.83%	49.11%	32.07%	24.38%	13.07%	4.33%	14.39%
Forward PE	-	-	-	-	-	19.56	17.09
No. Analysts	-	-	-	-	-	18	18

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	3.6B	4.5B
Avg	3.3B	3.8B
Low	3.0B	3.2B

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	13.2%	36.8%
Avg	4.3%	14.4%
Low	-5.2%	-4.1%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	36.30	41.78
Avg	29.07	33.25
Low	24.81	22.64

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	30.3%	43.7%
Avg	4.3%	14.4%
Low	-10.9%	-22.1%

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.